Drug intelligence / Profile preview

thiopropazate

Development stage: Discontinued
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral

Overview

Thiopropazate is a typical antipsychotic drug of the phenothiazine class. It acts as a prodrug to perphenazine and is used primarily for the treatment of psychosis. As a phenothiazine derivative, its mechanism of action involves antagonism at dopamine receptor (dopaminergic antagonist), which underlies its antipsychotic effects. Thiopropazate has also been studied for use in conditions such as tardive dyskinesia and Huntington’s chorea but is no longer commonly used or actively marketed in many regions[1][3][4][5].

Brand names: ArtalanDartalDartalanDartan
Other names: tiopropazatoThiopropazat

Targets

mAChR (Muscarinic acetylcholine receptors)ADRA1A (α1A)DRD2 (Dopamine D2 Receptor)HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on thiopropazate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on thiopropazate.

Explore the full profile